CELZ vs. AIM, PMCB, EVAX, APTO, SNTI, IKT, COEP, CLDI, ONVO, and TCBP
Should you be buying Creative Medical Technology stock or one of its competitors? The main competitors of Creative Medical Technology include AIM ImmunoTech (AIM), PharmaCyte Biotech (PMCB), Evaxion Biotech A/S (EVAX), Aptose Biosciences (APTO), Senti Biosciences (SNTI), Inhibikase Therapeutics (IKT), Coeptis Therapeutics (COEP), Calidi Biotherapeutics (CLDI), Organovo (ONVO), and TC Biopharm (TCBP). These companies are all part of the "biological products, except diagnostic" industry.
AIM ImmunoTech (NYSE:AIM) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, community ranking, risk, valuation, earnings and dividends.
In the previous week, Creative Medical Technology had 1 more articles in the media than AIM ImmunoTech. MarketBeat recorded 3 mentions for Creative Medical Technology and 2 mentions for AIM ImmunoTech. AIM ImmunoTech's average media sentiment score of 0.97 beat Creative Medical Technology's score of 0.74 indicating that Creative Medical Technology is being referred to more favorably in the news media.
Creative Medical Technology received 15 more outperform votes than AIM ImmunoTech when rated by MarketBeat users. However, 82.35% of users gave AIM ImmunoTech an outperform vote while only 68.93% of users gave Creative Medical Technology an outperform vote.
12.0% of AIM ImmunoTech shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 0.0% of AIM ImmunoTech shares are owned by insiders. Comparatively, 3.6% of Creative Medical Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
AIM ImmunoTech has a beta of -0.35, indicating that its share price is 135% less volatile than the S&P 500. Comparatively, Creative Medical Technology has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.
Creative Medical Technology has a net margin of 0.00% compared to Creative Medical Technology's net margin of -16,123.32%. AIM ImmunoTech's return on equity of -46.50% beat Creative Medical Technology's return on equity.
Creative Medical Technology has lower revenue, but higher earnings than AIM ImmunoTech. Creative Medical Technology is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.
Summary
Creative Medical Technology beats AIM ImmunoTech on 10 of the 15 factors compared between the two stocks.
Get Creative Medical Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CELZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Creative Medical Technology Competitors List
Related Companies and Tools
